Epigenetics in asthma: implications for treatable traits.

IF 3.4 Q2 ALLERGY
Frontiers in allergy Pub Date : 2026-09-07 eCollection Date: 2026-01-01 DOI:10.3389/falgy.2026.1929559
Vasiliki Apollonatou, Argyro Vrouvaki, Marina Moustaka Christodoulou, Athanasios Fengas, Stelios Loukides, Evangelia Fouka
{"title":"Epigenetics in asthma: implications for treatable traits.","authors":"Vasiliki Apollonatou, Argyro Vrouvaki, Marina Moustaka Christodoulou, Athanasios Fengas, Stelios Loukides, Evangelia Fouka","doi":"10.3389/falgy.2026.1929559","DOIUrl":null,"url":null,"abstract":"<p><p>Epigenetic mechanisms refer to heritable and potentially reversible modifications that regulate chromatin architecture and gene expression without altering the underlying DNA sequence. In asthma, these mechanisms provide a molecular interface between genetic susceptibility, environmental exposures, and immune dysregulation, contributing to disease heterogeneity and treatment response. The treatable traits paradigm, which focuses on the identification of specific modifiable biological and clinical characteristics, offers a clinically relevant framework for linking epigenetic changes to distinct molecular endotypes, enhancing mechanistic stratification beyond traditional phenotyping, thereby supporting precision medicine approaches. Emerging evidence suggests that epigenetic signatures have considerable potential as biomarkers for inflammatory endotyping and therapeutic stratification, although further validation is required before routine clinical implementation. In this mini review we will discuss epigenetic mechanisms involved in the development and maintenance of asthma processes, such as DNA methylation, histone modifications, and noncoding RNAs, focusing on their relevance to key treatable traits, including type 2 inflammation, corticosteroid responsiveness, airway remodeling, and exposure-driven disease.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"7 ","pages":"1929559"},"PeriodicalIF":3.4000,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591250/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/falgy.2026.1929559","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Epigenetic mechanisms refer to heritable and potentially reversible modifications that regulate chromatin architecture and gene expression without altering the underlying DNA sequence. In asthma, these mechanisms provide a molecular interface between genetic susceptibility, environmental exposures, and immune dysregulation, contributing to disease heterogeneity and treatment response. The treatable traits paradigm, which focuses on the identification of specific modifiable biological and clinical characteristics, offers a clinically relevant framework for linking epigenetic changes to distinct molecular endotypes, enhancing mechanistic stratification beyond traditional phenotyping, thereby supporting precision medicine approaches. Emerging evidence suggests that epigenetic signatures have considerable potential as biomarkers for inflammatory endotyping and therapeutic stratification, although further validation is required before routine clinical implementation. In this mini review we will discuss epigenetic mechanisms involved in the development and maintenance of asthma processes, such as DNA methylation, histone modifications, and noncoding RNAs, focusing on their relevance to key treatable traits, including type 2 inflammation, corticosteroid responsiveness, airway remodeling, and exposure-driven disease.

哮喘的表观遗传学:对可治疗性状的影响。
表观遗传机制是指在不改变潜在DNA序列的情况下调节染色质结构和基因表达的可遗传和潜在可逆的修饰。在哮喘中,这些机制提供了遗传易感性、环境暴露和免疫失调之间的分子界面,促进了疾病的异质性和治疗反应。可治疗特征范式侧重于识别特定的可改变的生物学和临床特征,为将表观遗传变化与不同的分子内型联系起来提供了一个临床相关的框架,增强了传统表型之外的机制分层,从而支持精准医学方法。新出现的证据表明,表观遗传特征作为炎症内分型和治疗分层的生物标志物具有相当大的潜力,尽管在常规临床实施之前需要进一步验证。在这篇小综述中,我们将讨论参与哮喘过程发展和维持的表观遗传机制,如DNA甲基化、组蛋白修饰和非编码rna,重点关注它们与关键可治疗特征的相关性,包括2型炎症、皮质类固醇反应性、气道重塑和暴露驱动型疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书